Christine Ambrosone

Has grant

Roswell Park Comprehensive Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Risk factors and molecular mechanisms for estrogen receptor negative breast cancer

Open Date: 2024-10-01

Close Date: 2025-09-30

Grant: Close

Risk factors and molecular mechanisms for ER negative breast cancer

Open Date: 2017-10-01

Close Date: 2018-09-30

Grant: Close

Cell-mediated Immunity and quality of life in breast cancer patients: a longitudinal study

Open Date: 2014-10-01

Close Date: 2015-09-30

Grant: Close

Cell-mediated immunity and quality-of-life in breast cancer patients: A Longitudinal Study

Open Date: 2012-07-24

Close Date: 2018-02-22

Grant: Close

Basal-like Breast Cancers in Black and White Women: an 'Out of Africa' Hypothesis

Open Date: 2010-07-30

Close Date: 2018-02-22

Articles (48)

Background: Research has linked neighborhood factors (e.g., air pollution, obesogenic environment) often associated with residential segregation to cancer disparities, including mortality. Limited research has explored these multilevel drivers of health, recognizing residential segregation as upstream of neighborhood social, built, and physical environment attributes. In this study, we describe the neighborhood data resource of the Pathways Study, a diverse cohort of women diagnosed with breast cancer. Methods: Using data from multiple sources, including the 2010 US Census, we appended census tract and block group-level measures that characterize the participants’ baseline neighborhoods. We examined distributions of neighborhood attributes by the Index of Concentration at the Extremes, a measure of racialized economic segregation, to demonstrate the relationships among these factors. Results: Twenty-eight percent of the participants resided in neighborhoods with the highest concentrations of high-income non-Hispanic White residents [i.e., most privileged neighborhoods; quintile (Q) 5] compared with only 9% who resided in neighborhoods with the highest concentrations of low-income residents from minoritized racial/ethnic groups (i.e., least privileged neighborhoods, Q1). Participants residing in less privileged neighborhoods had more exposure to detrimental neighborhood attributes, including a higher overall pollution burden, markers of physical disorder (e.g., graffiti and garbage), more barred windows, and a higher crime index. Conclusions: For a cohort of breast cancer survivors, residing in neighborhoods with less privilege shows evidence of adverse neighborhood attributes across domains of social, built, and physical environments. Impact: This neighborhood infrastructure is well positioned to assess interactions across the multilevel factors contributing to health disparities in women with breast cancer.

Year:

2026

Background: Research has linked neighborhood factors (e.g., air pollution, obesogenic environment) often associated with residential segregation to cancer disparities, including mortality. Limited research has explored these multilevel drivers of health, recognizing residential segregation as upstream of neighborhood social, built, and physical environment attributes. In this study, we describe the neighborhood data resource of the Pathways Study, a diverse cohort of women diagnosed with breast cancer. Methods: Using data from multiple sources, including the 2010 US Census, we appended census tract and block group-level measures that characterize the participants’ baseline neighborhoods. We examined distributions of neighborhood attributes by the Index of Concentration at the Extremes, a measure of racialized economic segregation, to demonstrate the relationships among these factors. Results: Twenty-eight percent of the participants resided in neighborhoods with the highest concentrations of high-income non-Hispanic White residents [i.e., most privileged neighborhoods; quintile (Q) 5] compared with only 9% who resided in neighborhoods with the highest concentrations of low-income residents from minoritized racial/ethnic groups (i.e., least privileged neighborhoods, Q1). Participants residing in less privileged neighborhoods had more exposure to detrimental neighborhood attributes, including a higher overall pollution burden, markers of physical disorder (e.g., graffiti and garbage), more barred windows, and a higher crime index. Conclusions: For a cohort of breast cancer survivors, residing in neighborhoods with less privilege shows evidence of adverse neighborhood attributes across domains of social, built, and physical environments. Impact: This neighborhood infrastructure is well positioned to assess interactions across the multilevel factors contributing to health disparities in women with breast cancer.

Year:

2026

Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.

Year:

2025

Objective Having children reduces risk of breast cancer overall, but parity without breastfeeding, more prevalent among black women, increases risk of poor-prognosis oestrogen receptor negative (ER−) breast cancer. We investigated if relationships between parity, breastfeeding and ER subtypes result from epigenetic programming, potentially steering breast progenitor cells to a basal-like phenotype. Methods and analysis The Illumina MethylationEPIC platform was used to assess genome-wide methylation in formalin-fixed, paraffin-embedded tumours from 1459 Black women with breast cancer. Methylation was evaluated in relation to parity, breastfeeding and breast cancer subtypes in a case-only analysis, with methylation-gene expression pairs tested in a subset of cases. We then performed functional enrichment analysis for probes significantly associated with parity and breastfeeding. Results Among women who did not breastfeed (n=634), there were 500 significant (p<1e−5) differentially methylated loci (DML) by parity, compared with only five DMLs among women who had breastfed their children (n=568). One of the top DML genes was FOXA1 , pivotal in governing the luminal lineage of progenitor cells, with a statistically significant interaction (p=0.04) for number of births and breastfeeding. Associations were strongest for ER− disease. Conclusion In this large study of Black women with breast cancer, we elucidated biological pathways for the observed associations between parity without breastfeeding and breast cancer subtypes, revealing distinct molecular alterations in breast DNA, particularly for ER− tumours. Black women in the USA tend to have more children and are less likely to breastfeed; their breast cancer risk may be reduced by societal systems that promote and support breastfeeding.

Year:

2025

Hazard ratios (HR) and 95% confidence intervals (95% CI) for the association of 2-year post-diagnosis lifestyle with all-cause mortality, breast cancer-mortality, and breast cancer recurrence among women diagnosed with stage I–III breast cancer.

Year:

2025

Hazard Ratios and 95% Confidence Intervals for Associations of each of the 9 Components of the 2-Year Post-Diagnosis Lifestyle Score with All-Cause Mortality, Breast Cancer-Specific Mortality, and Breast Cancer Recurrence, Excluding Deaths and Recurrences Occurring within 4 Years of Diagnosis.

Year:

2025

Subdistribution hazard ratios (sdHR) and 95% confidence intervals (95% CI) for the association of 2-year post-diagnosis lifestyle with breast cancer-specific mortality (n=1,736) and breast cancer recurrence (n=1,705).

Year:

2025

Posterior Median Hazard Ratios and 95% Credible Intervals from Piecewise Exponential Proportional Hazards Model for All-Cause Mortality, Breast Cancer-Specific Mortality, and Breast Cancer Recurrence in the Pathways Study

Year:

2025

Interactions Between the 2-Year Post-Diagnosis Lifestyle score and Selected Characteristics with All-Cause Mortality, Breast Cancer-Specific Mortality, and Breast Cancer Recurrence in the Pathways Study.

Year:

2025

Cumulative incidence of all-cause mortality, breast cancer-specific mortality, and breast cancer recurrence among women diagnosed with invasive breast cancer in the Pathways Study, according to tertiles of the 2-year post-diagnosis lifestyle score, 2006–2018

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (107)

Montserrat Garcia-Closas

Professor of Epidemiology

Institute of Cancer Research

UNITED KINGDOM
View details

Tomáš Zima

Head of Institute

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC
View details

Kathleen Claes

Full professor

Ghent University Hospital

BELGIUM
View details

Giuseppe Matullo

-

ITALY
View details

Pushkar Inamdar

University of California, San Francisco

UNITED STATES
View details

Lisa Wiesmüller

Professor

Ulm University

GERMANY
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Andriy Derkach

Associate Attending Biostatistician

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Lauren E. McCullough

-

UNITED STATES
View details

Jennifer Hu

Professor

University of Miami

UNITED STATES
View details

Eric Hahnen

-

GERMANY
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Sara Lindström

University of Washington

UNITED STATES
View details

Maria Rossing

Associate Clinical Professor

Copenhagen University Hospital

DENMARK
View details

Marco Montagna

Istituto Oncologico Veneto

ITALY
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Nicoletta Resta

Full Professor Medical Genetics

University of Bari Aldo Moro

ITALY
View details

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Maria Piane

Sapienza University of Rome

ITALY
View details

Sara González

Institut Català d'Oncologia

SPAIN
View details

Shiv Prakash Verma

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

FEI CHEN

Assistant Professor

University of Southern California

UNITED STATES
View details

Bo Qin

Associate Professor of Medicine

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Katie O'Brien

Staff Scientist

National Institute of Environmental Health Sciences

UNITED STATES
View details

Scarlett L. Gomez

University of California, San Francisco

UNITED STATES
View details

A Heather Eliassen

Professor

Harvard University

UNITED STATES
View details

Qiang Hu

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Tanish Gandhi

Ohio State University

UNITED STATES
View details

Lei Wei

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Alexandra Martins

INSERM

FRANCE
View details

Stefan Ambs

Senior Investigator (tenured) and Head of the Molecular Epidemiology Section

National Cancer Institute

UNITED STATES
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Clarice Weinberg

Principal Investigator

National Institute of Environmental Health Sciences

UNITED STATES
View details

Alexander E Volk

-

GERMANY
View details

Weang Kee Ho

Professor

Sunway University

MALAYSIA
View details

Wei Zheng

-

UNITED STATES
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Yara G Abdou

University of North Carolina at Chapel Hill

UNITED STATES
View details

Kitaw Demissie

Dean and Professor

SUNY Downstate Health Sciences University School of Public Health

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

W. Dana Flanders

Professor

Rollins School of Public Health

UNITED STATES
View details

Lindsay J Collin

Assistant Professor

Emory University

UNITED STATES
View details

Mariarosaria Calvello

European Institute of Oncology

ITALY
View details

Mario Schootman

Professor

University of Arkansas for Medical Sciences

UNITED STATES
View details

Qiuyin Cai

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

anna coppa

Sapienza University of Rome

ITALY
View details

Allison DePersia

NorthShore University HealthSystem

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Florentia Fostira

National Centre for Scientific Research-Demokritos

GREECE
View details

Paolo Radice

Head of Reserach Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Maria Elena. Martinez

University of California

UNITED STATES
View details

Marketa Janatova

Assistanf Professor and researcher

Přírodovědecká Fakulta, Univerzita Karlova

CZECH REPUBLIC
View details

Melissa A. Troester

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

John D. Carpten

City of Hope Comprehensive Cancer Center

UNITED STATES
View details

Elad Ziv

Professor

University of California

UNITED STATES
View details

GUOCHONG JIA

Vanderbilt University

UNITED STATES
View details

Andrew Olshan

University of North Carolina at Chapel Hill

UNITED STATES
View details

Gareth Evans

The University of Manchester

UNITED KINGDOM
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Charles F. Lynch

-

UNITED STATES
View details

Chi-Chen Hong

Associate Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Weng Khong Lim

Assistant Professor

Duke-NUS Medical School

SINGAPORE
View details

Barbara Pasini

Associate Professor of Medical Genetics

Università degli Studi di Torino

ITALY
View details

Dezheng Huo

University of Chicago

UNITED STATES
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Gordon Watt

Junior Group Leader

The Netherlands Cancer Institute

NETHERLANDS
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Xingyi Guo

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Jeffrey Weitzel

Professor and Director

University of Kansas Cancer Center

UNITED STATES
View details

Peggy Reynolds

Professor

University of California, San Francisco

UNITED STATES
View details

Jirong Long

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Julie Von Behren

University of California, San Francisco

UNITED STATES
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew G. Rundle

Professor

-

UNITED STATES
View details

Nereida Sotelo

Ohio State University

UNITED STATES
View details

Paul Auer

Professor

Medical College of Wisconsin

UNITED STATES
View details

Jo Freudenheim

SUNY Distinguished Professor and Associate Dean

University at Buffalo

UNITED STATES
View details

Hoda Anton-Culver

Professor and Chair

University of California, Irvine

UNITED STATES
View details

Amber Aeilts

Assistant Professor, Genetic Counselor

Ohio State University

UNITED STATES
View details

Terryl Hartman

Professor

Emory University

UNITED STATES
View details

Adana Llanos

Associate Professor, Tenured

Columbia University

UNITED STATES
View details

Alvaro Monteiro

Senior Member - Full Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Yaohua Yang

Assistant Professor

University of Virginia

UNITED STATES
View details

Corinna Ernst

Hannover Medical School

GERMANY
View details

Salma Shariff‐Marco

Professor

University of California, San Francisco

UNITED STATES
View details

Patrick Bradshaw

University of California, Berkeley

UNITED STATES
View details

Allison W Kurian

Professor

Stanford University School of Medicine

UNITED STATES
View details

Jian Gu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jesse J Plascak

co-Leader

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Kathryn Ruddy

Professor

Mayo Clinic

UNITED STATES
View details

Olufunmilayo I. Olopade

Professor

University of Chicago

UNITED STATES
View details

Lidia Feliubadaló

Institut Català d'Oncologia

SPAIN
View details

Christopher Li

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Koichi Matsuda

University of Tokyo

JAPAN
View details

Kimberly A. Bertrand

Associate Professor of Medicine

Boston University

UNITED STATES
View details

Bingshan Li

Vanderbilt University

UNITED STATES
View details

Joanne Ngeow

Head

Nanyang Technological University (NTU)

SINGAPORE
View details

Eric Polley

Associate Professor

University of Chicago

UNITED STATES
View details

Elisa Bandera

Chief

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Stephen Mooney

Associate Professor

University of Washington

UNITED STATES
View details

Zdenek Kleibl

Laboratory of oncogenetics (head)

Charles University, First Faculty of Medicine

CZECH REPUBLIC
View details

Nicholas Boddicker

Research Associate

Mayo Clinic

UNITED STATES
View details

Amanda Toland

Ohio State University

UNITED STATES
View details

Argyrios Ziogas

Professor

University of California, Irvine

UNITED STATES
View details

Laura Cortesi

University of Modena and Reggio Emilia

ITALY
View details